BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., trading under the ticker HLXB, is a publicly listed vehicle operating in the healthcare and oncology sector. The company filed a Form 10-Q with the SEC on May 15, 2025, under accession number 0001213900-25-044424, reflecting its status as an active reporting company subject to quarterly disclosure obligations. Focused on oncology therapeutics, HLXB sits within the biotech and life sciences segment of the SPAC and blank-check market, a corner of the space that has drawn sustained attention from healthcare-oriented sponsors in recent years. For complete filing history, deal timeline, and analytics on HLXB, sign up for full data access at SpacDesk.